id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-256143-9u5a0jqz	Grassia, Roberto	Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not?	2020-05-09		.txt	text/plain	535	45	56	title: Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? 1 In this setting, the initial indication from the inflammatory bowel disease (IBD) center in Wuhan was to discontinue all biological and immunosuppressive treatments. 3 In an Italian observational study, among 522 IBD patients (89% adults), 16% under biological therapy, none was hospitalized for COVID-19. Further studies are needed to investigate if IBD patients under biological treatment could be protected against the COVID-19 pneumonia, whereas those under immunosuppressive therapy (ie, thiopurines) could remain at higher risk of developing the disease due to the different mechanism of action. Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?	./cache/cord-256143-9u5a0jqz.txt	./txt/cord-256143-9u5a0jqz.txt